clinical data management News
-
Appointment of Cassandra Harrison to Vice President Clinical Operations and Data Management
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Ms Cassandra Harrison to the position of Vice President (VP) Clinical Operations and Data Management. Ms Harrison joins Chimeric with more than 10 years experience in clinical operations, compliance, and data ...
-
2KMM`s blog official opening and our participation in *R in Pharma 2020* conference
“A journey of a thousand miles begins with a single step” says Lao-Tzu / Chinese proverb /. With this blog post we start a unique series on our company’s blog. From this day forward, we will be sharing interesting (in our opinion) stories from the field of clinical biostatistics, data management in clinical trials and reporting news from a pioneering journey we started a few ...
-
Clinical Trial Managers Need to Know These Skills for the Future
The Covid-19 epidemic has changed the world in many ways, and many clinical trials have been done to research more about it. According to the World Health Organization (WHO), 12,969 clinical trials were done in America in 2021. Even in pre-pandemic times, clinical trials have always been an ongoing process. Clinical trial managers work on cutting-edge studies and contribute to ...
By Brio Group
-
endpoint and THREAD Simplify DCT Operations for Key Stakeholders to Reduce Study Timelines
endpoint Clinical, the leader in global interactive response technology (IRT®) for clinical trials, and THREAD, a leading technology and service provider enabling decentralized clinical trials (DCT), have announced their partnership to offer sponsors and sites a solution that simplifies DCT operations and reduces research study timelines. “Adoption of DCT technologies that are capable ...
-
New Study Confirms Daxor’s BVA-100 Volume Metric Compared to CardioMEMS Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. ...
-
Results of the PROSPECT II Natural History Study Demonstrate High-Risk Plaques Identified by NIRS+IVUS Imaging are Linked to Future Coronary Events
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced positive results from the PROSPECT II and PROSPECT ABSORB studies, presented today as a late-breaking clinical trial at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The PROSPECT II study demonstrated the ability of near-infrared spectroscopy ...
-
Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of iaF-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced publication of key results from its Phase 3 SPOTLIGHT trial of F-rhPSMA-7.3 in recurrent prostate cancer in an abstract being presented at the ASCO 2022. Genitourinary Cancers Symposium (ASCO GU). F-rhPSMA-7.3 is an investigational ...
-
Blue Earth Diagnostics Announces Results of an Analysis of the Impact of Axumin® (Fluciclovine F 18) PET/CT Imaging on Androgen Deprivation Therapy (ADT) Planning in Recurrent Prostate Cancer
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of a secondary, post-hoc analysis of data from the prospective LOCATE and FALCON clinical trials that evaluated the impact of Axumin® (fluciclovine F 18) PET/CT imaging on management of patients with recurrent prostate cancer. ...
-
Synaptive Medical Announces Close of $17M Preferred Share Financing
Synaptive Medical, a leader in automation and robotics, announced today it has completed a sale of preferred equity totaling $17,000,000 USD. The investment was made by Sensegain Group, a leading asset management firm in China. Ms. Jing Yang, Board Member & Senior Partner of Sensegain, will join Synaptive’s Board of Directors. Sensegain Group is headquartered in Beijing with multiple ...
-
Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
The GP2 Phase III clinical trial poster was presented in person at the 2021 annual San Antonio Breast Cancer Symposium (SABCS). The Company was a SABCS sponsor and held a clinical trial planning meeting with investigators at the conference. The poster can be seen here. Critical steps toward study initiation have been completed, including manufacturing, contracting with clinical trial partners, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you